Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent
Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by
P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by
intravascular imaging (IVUS or OCT)
Hypothesis: Tailored antiplatelet strategy (short DAPT followed by P2Y12 inhibitor alone) is
superior to conventional antiplatelet strategy in terms of clinically relevant bleeding and
noninferior for ischemic composite adverse events in patients who received intravascular
imaging-guided optimized DES implantation. (Optimized stent evaluated by on-site IVUS/OCT
could act as an essential criterion for decision making for tailored antithrombotic strategy)